New Pyridopyrimidone Derivatives: Synthesis, Molecular Docking Studies, and Potential Anticancer Activity


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

A new series of pyrido[2,3-d]pyrimidones incorporated pyrazoles and fused triazoles are synthesized and tested in vitro for cytotoxic effect against cancer cell lines: HePG-2, HCT-116, MCF-7, PC-3, and A-549. Their inhibition of protein kinase is assessed. The highest growth inhibitory (IC50 0.3 µM) effect is determined for one of compounds as compared with doxorubicin (IC50 0.6 µM). A modeling study is performed for approaching the compounds mode of binding and their similarity with the positive control drugs.

Ключевые слова

Об авторах

N. Khalifa

Pharmaceutical Chemistry Department, Drug Exploration and Development Chair (DEDC), College of Pharmacy; Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Division

Автор, ответственный за переписку.
Email: nkhalifa.c@ksu.edu.sa
Саудовская Аравия, Riyadh, 11451; Giza, Cairo, 12622

H. Alkahtani

Pharmaceutical Chemistry Department, College of Pharmacy

Email: nkhalifa.c@ksu.edu.sa
Саудовская Аравия, Riyadh, 11451

M. Al-Omar

Pharmaceutical Chemistry Department, Drug Exploration and Development Chair (DEDC), College of Pharmacy; Pharmaceutical Chemistry Department, College of Pharmacy

Email: nkhalifa.c@ksu.edu.sa
Саудовская Аравия, Riyadh, 11451; Riyadh, 11451

A. Bakheit

Pharmaceutical Chemistry Department, College of Pharmacy; Chemistry Department, Faculty of Science and Technology

Email: nkhalifa.c@ksu.edu.sa
Саудовская Аравия, Riyadh, 11451; Khartoum


© Pleiades Publishing, Ltd., 2019

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах